Jennison Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Jennison Associates’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-213,669	Closed	-$23.3M	–	643
2023 Q1	$23.3M	Sell	213,669 -310,009	-59%	-$34.3M	0.02%	306
2022 Q4	$59.6M	Sell	523,678 -1,217,432	-70%	-$101M	0.06%	162
2022 Q3	$108M	Buy	1,741,110 +420,629	+32%	+$29.4M	0.11%	107
2022 Q2	$105M	Sell	1,320,481 -72,313	-5%	-$6.85M	0.11%	108
2022 Q1	$147M	Buy	1,392,794 +42,399	+3%	+$4.13M	0.11%	96
2021 Q4	$146M	Buy	1,350,395 +392,451	+41%	+$42.8M	0.09%	94
2021 Q3	$105M	Buy	957,944 +12,339	+1%	+$1.28M	0.07%	114
2021 Q2	$88.5M	Buy	945,605 +24,579	+3%	+$2.26M	0.06%	136
2021 Q1	$84.8M	Buy	921,026 +72,279	+9%	+$6.1M	0.06%	141
2020 Q4	$62.1M	Buy	848,747 +22,794	+3%	+$1.69M	0.04%	172
2020 Q3	$64.2M	Sell	825,953 -301,441	-27%	-$20.7M	0.05%	143
2020 Q2	$62.7M	Sell	1,127,394 -867,747	-43%	-$37.1M	0.06%	137
2020 Q1	$59.1M	Buy	1,995,141 +37,787	+2%	+$1.28M	0.07%	121
2019 Q4	$70.9M	Sell	1,957,354 -589,683	-23%	-$18.1M	0.07%	151
2019 Q3	$69.4M	Buy	2,547,037 +176,419	+7%	+$4.56M	0.07%	154
2019 Q2	$57M	Buy	2,370,618 +167,929	+8%	+$4.26M	0.06%	190
2019 Q1	$58.2M	Sell	2,202,689 -17,878	-0.8%	-$424K	0.06%	199
2018 Q4	$43.4M	Buy	2,220,567 +807,401	+57%	+$15.8M	0.05%	234
2018 Q3	$27.7M	Buy	+1,413,166	New	+$26.9M	0.03%	351

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jennison Associates's HZNP Position: Q2 2023 in Review

Jennison Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 213,669 shares — an estimated $23.3M sold.

Jennison Associates first reported a position in HZNP in Q3 2018 and held it in 19 quarters. The position peaked at $147M in Q1 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Jennison Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Jennison Associates sold 213,669 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $23.3M.
Jennison Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 19 quarters.
Jennison Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $147M in Q1 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Jennison Associates's 13F filing for Q2 2023, filed 3 Aug 2023.